SBIR-STTR Award

Platform for Myocardial Infarct Mri and Delivery of Therapeutics
Award last edited on: 3/29/19

Sponsored Program
STTR
Awarding Agency
NIH : NHLBI
Total Award Amount
$379,160
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Eric T Ahrens

Company Information

Celsense Inc

603 Stanwix Street Suite 348
Pittsburgh, PA 15222
   (412) 263-2870
   info@celsense.com
   www.celsense.com

Research Institution

xx

Phase I

Contract Number: 1R41HL116014-01
Start Date: 8/20/12    Completed: 1/31/13
Phase I year
2012
Phase I Amount
$379,160
Myocardial infarction (MI) afflicts more than one million persons per year in the United States alone. MI results in permanent left ventricle (LV) scarring that causes diminished pump efficiency and, commonly, heart failure. Towards reduction or elimination of scarring, there is increasing interest in reparative biological materials, such as cells and proteins, that are introduced into the affected region of the LV early after MI. We believe that such an approach will eventually become part of a standard of care. The most promising route for the delivery of such materials is direct LV injection (DLVI). Thus far, the utility of DLVI has been hampered by the lack methods for accurate spatial targeting of affected tissue. This has greatly impeded clinical translation of promising materials. The goal of this project is to devise cutting edge imaging tools to visualize infarcted regions using MRI.

Public Health Relevance Statement:
Myocardial infarction (MI) afflicts more than one million persons per year in the United States. Emerging therapeutic strategies for MI involve direct injection of therapeutic biological materials, such as stem cells, into the affected heart regions (i.e., inflamed tissue). A way to reliably visualize the affected areas of the heart to guide delivry is a key unmet need. This proposal will evaluate the use of new magnetic resonance imaging technologies developed by Celsense, Inc., that can be used to visualize the inflammation associated with MI and enable effective therapeutic delivery.

NIH Spending Category:
Bioengineering; Cardiovascular; Clinical Research; Diagnostic Radiology; Health Services; Heart Disease; Heart Disease - Coronary Heart Disease

Project Terms:
Adoption; Affect; Area; base; Biocompatible Materials; Cardiac; Cells; Cicatrix; Clinical; clinically relevant; Computer software; Cues; Data; Detection; Development; Emulsions; Engineering; Family suidae; Fluorine; Fluorocarbons; Goals; Gold; Heart; Heart failure; Image; Imagery; Imaging Device; Imaging technology; Infarction; Inflammation; Inflammatory; Injection of therapeutic agent; interest; intravenous injection; Label; Left ventricular structure; Location; macrophage; Magnetic Resonance Imaging; Manuals; Methods; Modeling; Myocardial Infarction; Myocardium; Persons; Procedures; Process; Proteins; Pump; Reagent; response; Route; Signal Transduction; Site; standard of care; Stem cells; Therapeutic; Tissues; Translations; United States; Validation; Visualization software

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----